| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HPGDS |
| Uniprot No | O60760 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-199aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMPNYKL TYFNMRGRAE IIRYIFAYLD IQYEDHRIEQ ADWPEIKSTL PFGKIPILEV DGLTLHQSLA IARYLTKNTD LAGNTEMEQC HVDAIVDTLD DFMSCFPWAE KKQDVKEQMF NELLTYNAPH LMQDLDTYLG GREWLIGNSV TWADFYWEIC STTLLVFKPD LLDNHPRLVT LRKKVQAIPA VANWIKRRPQ TKL |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于 **HPGDS(造血前列腺素D合成酶)重组蛋白** 的模拟参考文献示例(部分信息基于真实研究领域，但文献标题和作者为示例性内容)：
---
1. **文献名称**: *"High-yield expression and purification of human HPGDS recombinant protein in E. coli for structural studies"*
**作者**: Tanaka, K. et al.
**摘要**: 本研究优化了人源HPGDS在大肠杆菌中的重组表达条件，通过亲和层析和凝胶过滤纯化获得高纯度蛋白，并验证其酶活性和热稳定性，为后续晶体结构解析奠定基础。
2. **文献名称**: *"Crystal structure analysis of HPGDS reveals substrate-binding mechanism and potential drug target sites"*
**作者**: Zhang, Y. et al.
**摘要**: 通过解析HPGDS重组蛋白的X射线晶体结构，揭示了其催化活性中心的关键氨基酸残基与底物PGH2的结合模式，提出针对该酶的抑制剂设计策略。
3. **文献名称**: *"Functional characterization of recombinant HPGDS in mast cell-mediated allergic inflammation"*
**作者**: Smith, J. et al.
**摘要**: 利用昆虫细胞表达系统制备重组HPGDS，验证其在肥大细胞中促进PGD2合成的功能，并证明抑制HPGDS可减轻小鼠模型的过敏性炎症反应。
---
如需真实文献，建议通过 **PubMed** 或 **Google Scholar** 检索关键词(如 "HPGDS recombinant protein expression"、"HPGDS structure")。实际研究中，HPGDS重组蛋白常用于药物开发(如抗过敏/抗炎药物靶点)和酶学机制解析。
**Background of HPGDS Recombinant Protein**
Hematopoietic Prostaglandin D Synthase (HPGDS) is a key enzyme in the biosynthesis of prostaglandin D₂ (PGD₂), a lipid mediator involved in diverse physiological and pathological processes. HPGDS catalyzes the isomerization of prostaglandin H₂ (PGH₂) to PGD₂, which is further metabolized into bioactive compounds like 15-deoxy-Δ¹²,¹⁴-PGJ₂. Primarily expressed in hematopoietic cells, including mast cells, macrophages, and Th2 lymphocytes, HPGDS plays a critical role in regulating inflammation, allergic responses, and immune homeostasis.
PGD₂, via its receptors DP1 and DP2 (CRTH2), modulates immune cell recruitment, vascular permeability, and smooth muscle contraction. HPGDS-derived PGD₂ is implicated in allergic diseases (e.g., asthma, atopic dermatitis), neuroinflammation, and tumor progression. Notably, HPGDS is linked to neuroprotection in neurodegenerative disorders like Alzheimer’s disease, though its dual roles in pro- and anti-inflammatory pathways remain under investigation.
Recombinant HPGDS protein, produced via heterologous expression systems (e.g., *E. coli*, insect cells), retains enzymatic activity and structural integrity, enabling functional studies. It is widely used to elucidate HPGDS-PGD₂ signaling mechanisms, screen inhibitors for therapeutic development, and study protein-ligand interactions. As a potential drug target, HPGDS inhibitors are being explored for treating allergies, autoimmune diseases, and cancer.
Overall, HPGDS recombinant protein serves as a vital tool for decoding PGD₂ biology and advancing targeted therapies, highlighting its significance in both basic research and translational medicine.
×
